Schizophrenia neurocognitive domain profiles are predominantly based on paper-and-pencil batteries. This study presents the first schizophrenia domain profile based on the Computerized Multiphasic Interactive Neurocognitive System (CMINDS®). Neurocognitive domain z-scores were computed from computerized neuropsychological tests, similar to those in the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB), administered to 175 patients with schizophrenia and 169 demographically similar healthy volunteers. The schizophrenia domain profile order by effect size was Speed of Processing (d=-1.14), Attention/Vigilance (d=-1.04), Working Memory (d=-1.03), Verbal Learning (d=-1.02), Visual Learning (d=-0.91), and Reasoning/Problem Solving (d=-0.67). There were no significant group by sex interactions, but overall women, compared to men, showed advantages on Attention/Vigilance, Verbal Learning, and Visual Learning compared to Reasoning/Problem Solving on which men showed an advantage over women. The CMINDS can readily be employed in the assessment of cognitive deficits in neuropsychiatric disorders; particularly in large-scale studies that may benefit most from electronic data capture.
Bibliographical noteFunding Information:
Dr. Van Erp consulted for Roche Pharmaceuticals and has a contract with Otsuka Pharmaceutical Co., Ltd. (OPCJ). Dr. Bustillo consulted with Novartis and Otsuka Pharmaceuticals. Dr. Mathalon is a consultant for Bristol-Myers Squibb and consulted for Roche Pharmaceuticals. Dr. Preda consulted for Boehringer-Ingelheim. Dr. Potkin has financial interests in Bristol-Myers Squibb, Eisai, Inc., Eli Lilly, Forest Laboratories, Genentech, Janssen Pharmaceutical, Lundbeck, Merck, Novartis, Organon, Pfizer, Roche, Sunovion, Takeda Pharmaceutical, Vanda Pharmaceutical, Novartis, Lundbeck, Merck, Sunovion and has received grant funding from Amgen, Baxter, Bristol-Myers Squibb, Cephalon, Inc., Eli Lilly, Forest Laboratories, Genentech, Janssen Pharmaceutical, Merck, Otsuka, Pfizer, Roche, Sunovion, Takeda Pharmaceutical, Vanda Pharmaceutical, NIAAA, NIBIB, NIH/NCRR, University of Southern California, UCSF, UCSD, Baylor College of Medicine. The remaining authors declare no potential conflict of interest. None of the authors of this manuscript are affiliated with or receive compensation from NeuroComp Systems, Inc., MATRICS Assessment, Inc., or Neurcog Trials, Inc.
This work was supported by the National Center for Research Resources at the National Institutes of Health, USA (grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network) and NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org )). The funding sources had no role in the study design, conduct of the study, data collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Dr. Van Erp had full access to all of the data in the study, conducted the statistical analysis, and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors critically reviewed the manuscript, provided comments, and approved the manuscript for publication.
© 2015 Elsevier Ireland Ltd.
- Speed of processing